Category Archives: pricing

UK: Further Steps Toward Value-Based Assessment

By Leela Barham. The National Institute for Health and Care Excellence (NICE) has finally published the formal consultation on value-based assessment (VBA). VBA is the new VBP, incorporating a wider assessment of value and no longer clearly linking to price in quite the way that some speculated all the way back in 2010 when VBP […]
Also posted in Europe, Guest Blog, Op-Ed, Regulatory | Tagged , , , , , , | Leave a comment

UK Drug Pricing: An ICER of Zero?

by Leela Barham The incremental cost effectiveness ratio (ICER) – or the threshold for determining whether the costs of a new medicine are worth it – has been controversial since it’s inception. There are those who deny that anyone can put a price-tag on life; those that accept the concept but are happy to let […]
Also posted in Europe, Guest Blog, healthcare, Legal, Market Access, Regulatory, Strategy | Tagged , , , , , | Leave a comment

Innovation Drops Down NICE’s Value Agenda

Innovation as a consideration of value-based pricing decisions will be conspicuous by its absence in future NICE decisions. Omar Ali, a UK formulary development pharmacist and consultant to NICE, speaking at eyeforpharma’s Barcelona 2014 conference on Wednesday, explained that the UK price watchdog will prioritize considerations of wider societal benefit and unmet need as it […]
Also posted in Europe, Events | Tagged , , , , , | Leave a comment

Casing Cancer: ASCO Launches New Series on State of the Disease

Despite its importance as a vital indicator of overall population health status, cancer suffers from an information deficit – particularly when considered from a global perspective. The American Society of Clinical Oncology [ASCO], the lead professional group in this space, is now working to rectify at least part of the gap with the launch of […]
Also posted in healthcare, leadership, Market Access, R&D, Regulatory, Safety, Strategy | Tagged , , , , , | Leave a comment

Europe: Whatever Happened to Faster Reimbursement for Generics?

The plan to accelerate generic pricing and reimbursement has become another tragic European casualty, writes Brussels correspondent Reflector.
Also posted in Europe, Op-Ed, Regulatory | Tagged , , , , , | Leave a comment
  • Categories

  • Meta